Early Management of Type 2 Diabetes Mellitus

Stanley H. Hsia, MD

Module 1: Diagnosis and Screening, Pathophysiology, Treatment Targets and Nonpharmacological Treatment

Module 2: Pharmacological Options

Module 3: Screening And Management Of End-Organ Complications

Introduction

Dr. Stanley Hsia, Charles R. Drew University of Medicine and Science, will provide an overview of the clinical management principles for type 2 diabetes mellitus, based on current guidelines and evidence-based recommendations. Dr.Hsia will also review the current diagnostic criteria and screening recommendations for type 2 diabetes and a brief overview of the underlying pathophysiological concepts which will highlight the currently recommended treatment targets. Principles of nonpharmacological management will be followed by an overview of the approved pharmacological options. Finally, he will conclude with an overview of the screening and preventive management for the classic end-organ complications.

Intended Audience

This continuing medical education program is intended for primary care physicians and other healthcare professionals who manage patients with type 2 diabetes.

Educational Objectives

After completing this activity, participants should be better able to:

Use ADA criteria to diagnose type 2 diabetes
Explain the pathophysiology of diabetes and interactions of peripheral tissues, the liver, and beta-cells as potential targets of therapy
Identify recommended treatment targets and introduce non-pharmacological therapies and principles (ie, nutrition, physical activity, and diabetes education)
Describe the actions, advantages, and disadvantages of the major classes of oral agents used in the management of type 2 diabetes
Provide recommendations for surveillance and preventive management of end-organ complications in patients with type 2 diabetes

Information on CME credit

The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American Medical Association designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Nonphysicians may receive a certificate of participation for completing this activity.

Instructions for CME credit

This online enduring material is presented as an audio webcast with attendant slide presentation. To receive credit, please view all of the presentations of this CME activity and evaluate the content presented. Complete both the pre- and post-test and activity evaluation.

The estimated time to complete this activity, including pre-test, review of the materials, and self-assessment and evaluation is 1.0 hour.

Advisory Board

Stanley H. Hsia, MD, FRCPC, FACE, Chair
Program Director, Endocrinology, Metabolism & Molecular Medicine
Assistant Professor of Medicine, Division of Endocrinology and Metabolism
Charles R. Drew University of Medicine and Science
UCLA School of Medicine
Los Angeles, CA

Daniel Einhorn, MD, FACP, FACE
Medical Director, Scripps Whittier Institute for Diabetes
Clinical Professor of Medicine, UCSD
President, Diabetes and Endocrine Associates
La Jolla, CA

Martin S. Lipsky, MD
Dean, University of Illinois College of Medicine at Rockford
Professor, Department of Family and Community Medicine
Rockford, IL

Col. Robert A. Vigersky, MD
Director, Diabetes Institute
Walter Reed Health Care System
Clinical Associate Professor, Department of Medicine
Georgetown University School of Medicine
Washington, DC

Editorial Board

R. Mark Evans, PhD
Director, Healthcare Education Products and Standards
American Medical Association
Chicago, IL

Kristi Eidsvoog, PhD
Content Manager
MedEd Architects, LLC
Chicago, IL

Patti Fitzgerald
Manager, Product Development, Healthcare Education Products and Standards
American Medical Association
Chicago, IL

Faculty

Disclosure Policy

In order to assure the highest quality of CME programming, and to comply with the ACCME Standards for Commercial Support, the AMA requires that all faculty and planning committee members disclose relevant financial relationships with any commercial or proprietary entity producing health care goods or services relevant to the content being presented. We therefore obtain a completed disclosure and attestation form to inform the participant of any pertinent relationships disclosed, provided here.

These materials have been peer-reviewed by the members of the CME Advisory Board and the AMA Editorial Board to ensure the continued scientific accuracy and medical relevance of information presented and its independence from commercial bias. The AMA has control over all final

Dr. Einhorn: Research Grants, Aventis, Allergan, Lilly, Medtronic, Pfizer, sanofi-aventis;
Consultant, Amylin, Lilly, MannKind, Medtronic, Takeda; Speaker???s Bureau,
Amylin, Merck, sanofi-aventis, Takeda; Significant Shareholder, MannKind.

Dr. Hsia: Consultant, Merck

Dr. Lipsky: Nothing relevant to disclose

Dr. Vigersky: Research Grants, DexCom, NovoNordisk, Pfizer, Roche; Stockholder, Merck

Dr. Eidsvoog: Nothing relevant to disclose

Dr. Evans: Nothing relevant to disclose

Ms. Fitzgerald: Nothing relevant to disclose

Acknowledgement of Support

This CME publication was supported through an independent education grant from Takeda Pharmaceuticals and produced in accordance with the AMA Standards for Industry-Supported Multimedia Continuing Medical Education and Other Communications.